Advanced Management of Acute Intermittent Porphyria: The Role of Givosiran Therapy in Improving Long‐Term Outcomes‐A Case Study
Authors:
- Natália Rebeca Alves de Araújo KarpejanyNKNatália Rebeca Alves de Araújo Karpejany
- Jose Tiburcio Do Monte NetoJNJose Tiburcio Do Monte Neto
- Ester Miranda PereiraEPEster Miranda Pereira
- Isabel Andrea Ferreira CarvalhoICIsabel Andrea Ferreira Carvalho
- Rafael Melo Santos de Serpa BrandãoRBRafael Melo Santos de Serpa Brandão
- Adalberto Socorro da SilvaASAdalberto Socorro da Silva
- Tiberio Silva Borges dos SantosTSTiberio Silva Borges dos Santos
- Semiramis Jamil Hadad Do MonteSMSemiramis Jamil Hadad Do Monte
Open Access
- 5 July 2026
- journal article
- Published by Wiley in Clinical Case Reports
- Vol. 14 (7) , e73012
Abstract
Acute intermittent porphyria is a rare disorder causing neurotoxic precursor accumulation and severe neurological complications. We report a case progressing to tetraplegia and respiratory failure with delayed diagnosis. Treatment with hemin and givosiran resulted in prevention of attacks and functional recovery, highlighting the importance of early diagnosis and long‐term therapy.Keywords
This publication has 19 references indexed in Scilit:
- Nivolumab-associated IgA Nephropathy in a Child With Malignant MelanomaJournal of Pediatric Hematology/Oncology, 2024
- Update on heme biosynthesis, tissue‐specific regulation, heme transport, relation to iron metabolism and cellular energyLiver International, 2024
- HMBS gene mutations and hydroxymethylbilane synthase activity in acute intermittent porphyria: A systematic reviewMedicine, 2023
- Comment on “Association of clinical factors to functional outcomes in patients with stroke with large-vessel occlusion after endovascular thrombectomy”Journal of the Formosan Medical Association, 2023
- AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewGastroenterology, 2023
- UniProt: the Universal Protein Knowledgebase in 2023Nucleic Acids Research, 2022
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaNew England Journal of Medicine, 2020
- Heme biosynthesis and the porphyriasMolecular Genetics and Metabolism, 2019
- Acute hepatic porphyrias: Recommendations for evaluation and long‐term managementHepatology, 2017
- R325X mutation in exon 15 of the hydroxymethylbilane synthase gene identified in two Danish families with acute intermittent porphyriaClinical Chemistry, 1996